StockMirror — Stock Screener

INDGN Q2 FY27 Results & Earnings Analysis

Sentiment: Good (Confidence: high)

Earnings Summary

Indegene delivered strong Q2 FY27 results with revenue of INR11,223M (US$117.5M), up 39.5% YoY and 5.6% QoQ in INR terms, marking 5 consecutive quarters of >5% QoQ growth. EBITDA was INR1,873M at 16.7% margin (up 32% YoY) despite ~150 bps wage hike impact and lower interest income. PAT was INR1,123M (10% of revenue, up 10% YoY). Client base expanded to 107 active clients with 59 >$1M and 13 >$10M. Nine deal wins with ~$1M ACV including 3 large deals. BioPharm integration delivering with ~$1.5M cost synergies and >15% revenue growth trajectory. Management expects FY27 organic growth better than FY26, H2 stronger than H1, and EBITDA margins back to 19%+ by Q4 with margin growth outpacing revenue growth. Key risks include Tectonic ramp-up delays and change management challenges at largest client, offset by strong industry tailwinds from record pharma funding, approvals, and pipeline expansion.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management explicitly targets both organic growth better than FY26 and quarterly EBITDA margins back to 19%+ by Q4. Confidence in achieving both from: wage cycle fully in base, outcome-linked omnichannel contract progressing, deal wins with healthy pipeline, and go-to-market investments beginning to

About Indegene Limited

Indegene Limited (INDGN) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More